Join to view full profile
6530 TroostSte A17Kansas City, MO 64131
Phone+1 816-361-0670
Fax+1 816-444-6936
Dr. Hebbar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Nephrology, 1993 - 1995
Hennepin HealthcareResidency, Internal Medicine, 1989 - 1992
Tulane University School of MedicineClass of 1989
Certifications & Licensure
MO State Medical License 1995 - 2027
Clinical Trials
- CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS Start of enrollment: 2018 Mar 12
- A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis Start of enrollment: 2019 Jan 06
Publications & Presentations
PubMed
- 23 citationsOrai1 calcium channel inhibition prevents progression of chronic pancreatitis.Viktória Szabó, Noémi Csákány-Papp, Marietta Görög, Tamara Madácsy, Árpád Varga
JCI Insight. 2023-07-10 - 30 citationsAuxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial.Charles Bruen, Mukhtar Al-Saadi, Edward A Michelson, Maged Tanios, Raul Mendoza-Ayala
Critical Care. 2022-04-08 - Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activa...Charles Bruen, Joseph Miller, John Wilburn, Caleb Mackey, Thomas L Bollen
Pancreas. 2021-04-01
Press Mentions
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial HypertensionNovember 12th, 2025- CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory FailureJune 25th, 2025
- CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA Trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT ConferenceMarch 4th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
